<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028751</url>
  </required_header>
  <id_info>
    <org_study_id>KB-LANRA- 1001</org_study_id>
    <nct_id>NCT05028751</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination With the FLT3 Inhibitor Gilteritinib, in Patients With FLT3-mutated Relapsed or Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kronos Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kronos Bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in&#xD;
      combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in&#xD;
      participants with relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and 2: Number of Participants who Experience a Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Cycle 1 Day 1 through 30 days after last dose (up to approximately 5 years; cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of Participants who Experience a Dose-Limiting Toxicity (DLT) for Lanraplenib (LANRA)</measure>
    <time_frame>Cycle 1 Day 1 through pre-dose Cycle 2 Day 1 (cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximally Tolerated Dose (MTD) of Lanraplenib (LANRA)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Recommended Phase 2 Dose (RP2D) of Lanraplenib (LANRA)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (cycle is 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximal Plasma Concentration (Cmax) of Lanraplenib (LANRA)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to Maximal Plasma Concentration (Tmax) of Lanraplenib (LANRA)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration x Time Curve from Hour 0 to the Last Measurable Time Point (AUC0-last) of Lanraplenib (LANRA)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Composite Complete Response (CR) Rate</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Composite Complete Response (CR) with Partial Hematologic Recovery (CRh)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Duration of Response (DoR)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Event Free Survival (EFS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Relapsed Acute Myeloid Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential cohorts of participants will receive escalating doses of lanraplenib (LANRA) once daily (QD) + gilteritinib QD in each 28 day cycle for determination of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of LANRA in combination with gilteritinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following identification of the maximally tolerated dose (MTD) / recommended Phase 2 dose (RP2D) of lanraplenib (LANRA) in combination with gilteritinib in Part 1, an expansion cohort will enroll. The expansion cohort will receive LANRA in combination with gilteritinib at the MTD / RP2D once daily (QD) in each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanraplenib</intervention_name>
    <description>Orally via tablets</description>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: Expansion Cohort</arm_group_label>
    <other_name>LANRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gilteritinib</intervention_name>
    <description>Orally via tablets</description>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: Expansion Cohort</arm_group_label>
    <other_name>XOSPATA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥18 years of age with acute myeloid leukemia (AML) and at least 1 prior line of&#xD;
             therapy&#xD;
&#xD;
          -  FMS-like tyrosine kinase 3 (FLT3)-mutated disease documented in a local reference&#xD;
             laboratory&#xD;
&#xD;
          -  Have the ability to understand the requirements and procedures of the study and sign a&#xD;
             written informed consent form&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2&#xD;
&#xD;
          -  Adequate hepatic and renal function&#xD;
&#xD;
          -  Prothrombin time (PT), activated partial thromboplastin time (aPTT) and international&#xD;
             normalized ratio (INR) ≤1.5x upper limit of normal (ULN) unless receiving therapeutic&#xD;
             anticoagulation&#xD;
&#xD;
          -  Negative serum ß-human chorionic gonadotropin (HCG) test in women of child-bearing&#xD;
             potential (WOCBP)&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥50% confirmed by echocardiogram (ECHO) or&#xD;
             multi-gated acquisition (MUGA) scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement with leukemia&#xD;
&#xD;
          -  Failure to achieve at least a partial response (PR) or have relapsed following prior&#xD;
             exposure to gilteritinib or other next-generation FLT3 inhibitor monotherapy (eg.&#xD;
             quizartinib, crenolanib)&#xD;
&#xD;
          -  Clinical signs/symptoms of leukostasis that have failed therapy including hydroxyurea&#xD;
             and/or leukapheresis of at least 3 days duration&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Active infection with hepatitis B, C or known human immunodeficiency virus (HIV)&#xD;
             infection&#xD;
&#xD;
          -  Disseminated intravascular coagulation with active bleeding or signs of thrombosis&#xD;
&#xD;
          -  Known active coronavirus disease 2019 (COVID-19)&#xD;
&#xD;
          -  Administration of a live attenuated virus vaccine within 35 days before Cycle 1 Day 1&#xD;
             (C1D1)&#xD;
&#xD;
          -  History of non-myeloid malignancy except for the following: adequately treated&#xD;
             localized basal cell or squamous cell carcinoma of the skin; cervical carcinoma in&#xD;
             situ; superficial bladder cancer; asymptomatic prostate cancer without known&#xD;
             metastatic disease, with no requirement for therapy or requiring only hormonal therapy&#xD;
             and with normal prostate specific antigen for &gt; 1 year prior to start of study&#xD;
             therapy; or any other cancer that has been in complete remission without treatment for&#xD;
             ≥3 years prior to enrollment&#xD;
&#xD;
          -  Clinically significant heart disease&#xD;
&#xD;
          -  Prolongation of the congenital long measure between Q wave and T wave in the&#xD;
             electrocardiogram (QT) interval at baseline&#xD;
&#xD;
          -  Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection at the&#xD;
             time of study treatment initiation&#xD;
&#xD;
          -  Current (within 30 days of study enrollment) drug-induced liver injury, chronic active&#xD;
             hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary&#xD;
             cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver,&#xD;
             orportal hypertension&#xD;
&#xD;
          -  Ongoing (within 6 weeks of study enrollment) hepatic encephalopathy&#xD;
&#xD;
          -  Ongoing immunosuppressive therapy, including systemic chemotherapy for treatment of&#xD;
             leukemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director of Clinical Operations</last_name>
    <phone>650-484-1583</phone>
    <email>clinicaltrials@kronosbio.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Lanraplenib</keyword>
  <keyword>LANRA</keyword>
  <keyword>Relapsed Acute Myeloid Leukemia</keyword>
  <keyword>Refractory Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

